SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IGT ((VSE:IGT) Blockbuster Anti-Cancer Test Results !!!
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Culver who wrote (67)10/1/1999 1:36:00 AM
From: Spiney   of 94
 
IGT Pharma presents to international meeting on brain receptor technology

IGT Pharma Inc IGT
Shares issued 8,819,820 Sep 29 close $0.80
Thu 30 Sept 99 News Release
Mr. Bruce Schmidt reports
Results of recent advances in IGT's neurological drug development programs
were presented on September 22 to the third international meeting on
metabotropic glutamate receptors held in Sicily.
The purpose of the meeting was to bring together scientists from leading
academic, biotech and pharmaceutical organizations to report on
leading-edge research relating to the use of metabotropic glutamate
receptor technology in the treatment of neurological disorders. The mGluRs
are now widely accepted as being the basis for a new generation of
neurological drugs promising to treat neurological dysfunction more
effectively and specifically than currently available treatments.
Dr. Ken Curry, IGT's vice-president of research and development, presented
various aspects of IGT's neuroprotective drug program, including data
relating to the ability of the new drug, IGT 440103, to protect rodent
brain cells from damage related to oxygen deprivation, a condition related
to human stroke.
Initial partnering and collaboration discussions were initiated during the
meeting that may lead to expanded relationships with academic institutions
and pharmaceutical organizations wishing to use IGT's technology. IGT and
Dr. Curry have been acknowledged as leaders in the discovery of novel amino
acids that efficiently interact with the mGluR system.
IGT has recently patented five broad classes of rationally synthesized
amino acids that may represent new possibilities in the treatment of
stroke, epilepsy, as well as psychiatric conditions such as schizophrenia
and anxiety.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News